ANTX
An2 Therapeutics Inc
NASDAQ · Pharmaceuticals
$1.09
+0.03 (+2.83%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.24M | 7.98M | 7.65M |
| Net Income | 1.80M | 1.81M | 1.71M |
| EPS | — | — | — |
| Profit Margin | 21.9% | 22.7% | 22.3% |
| Rev Growth | -4.4% | +17.2% | +22.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 12.13M | 12.55M | 11.92M |
| Total Equity | 8.40M | 9.18M | 9.24M |
| D/E Ratio | 1.44 | 1.37 | 1.29 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.67M | 3.33M | 3.32M |
| Free Cash Flow | 1.39M | 970.9K | 896.1K |